The US stock market is doing great despite the mild correction at the beginning of this week. The OTCQX Composite, which tracks over 400 OTC companies, is flashing red on June 16, following the major indexes, such as the S&P 500.
The reopening economy is felt by most industries, but inflation worries are spoiling the party. On Tuesday, the US Labor Department said its producer price index rose 0.8% last month after adding 0.6% in April. Analysts expected an increase of 0.3% for May. In the 12 months through May, the index rose 6.6%, the largest move since November 2010.
Meanwhile, separate data showed that retail sales fell more than expected last month, though the general trend is resilient. US consumers started to spend more on services rather than goods, as vaccinations allow people to travel and engage in activities that were restricted during the pandemic. The April figure was revised sharply up and is well above the pre-COVID level.
Tim Quinlan of Wells Fargo told Reuters:
“The days of spending money online and splurging on durable goods and home furnishings is pivoting toward getting ready for trips to see grandma and grandpa at the lake or the beach and evenings out reconnecting with friends at bars and restaurants.”
All eyes and ears were on the Fed, which kept rates unchanged but signaled that rates may rise in 2023!! Investors over-reacted and sold on this news.
All in all, the US economy is recovering and providing great opportunities for investors.
NOW IS A GREAT TIME TO BUY OTC STOCKS
This is a great time to invest in OTC stocks, as the US and the global economy are gradually recovering from the devastating impact of the COVID-19 pandemic.
With blue chips, you can’t generate substantial returns given their massive market cap. One option would be to employ leverage, but it is risky, and there are few brokers and trading instruments that allow leverage on major stocks.
The good news is that there are OTC stocks with robust fundamentals that are trading at bargain prices, and we’re here to bring them to light.
Generally speaking, trading OTC stocks is much easier than getting exposure to blue chips. You don’t need a big account, and it’s technically extremely easy to make the first steps. All you need is a laptop and a brokerage account.
Nevertheless, you should keep in mind that small-cap stocks are subject to enormous volatility like what we have witnessed in the February-April period.
Also, remember these two important points when it comes to investing in small caps.
- Buy low and sell high.
- Don’t be afraid to book profits.
However, don’t rush to book profits too early.
Finding the right balance is not that difficult if you’re not getting too greedy and stay disciplined.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
The key to trading small caps is finding momentum BEFORE it happens and then be patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
We recommend you to own a portfolio of small-cap stocks. For some, that can be as many as 10 to 20 or more OTC stocks. Obviously, our recommendation to build a portfolio means that day trading is not an option for us. Day trading doesn’t suit our personality, and we don’t like the intraday moves markets make. We have found we made more money being patient and ignoring the day-to-day noise of the markets.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
Today, we’ll share 4 OTC stocks that are currently trending. Here they are: APT Systems Inc (OTCPK: APTY), DarkPulse Inc (OTCPK: DPLS), Oncology Pharma Inc (OTCPK: ONPH), and RushNet, Inc. (OTC: RSHN).
OTC Stock to Watch #1 APTY
APT Systems Inc is in a bullish mode right now, gaining 24% on June 16 and 360% over the past five days. The price has surged from $0.0014 at the end of May to the current level of $0.01555, which is the highest since the end of 2018.
The fintech firm ceased to be a reporting company exactly one year ago when it announced its decision to file Form 15 with the Securities and Exchange Commission (SEC). At the time, APTY’s Board of Directors considered the costs associated with the preparation and filing of reports and determined that the limited resources of the company could be better spent on building business operations, especially given the economic crisis caused by the pandemic. Since then, APTY hasn’t filed any reports, including 10-K, 10-Q, and 8-K.
Nevertheless, APTY is now working to become Pink Current.
APT Systems, working with the OTCmarkets, has already submitted its application for filing eligibility and paid all required fees. Financials are being readied for submission when approval is advised. $APTY
— APT Systems Inc APTY (@APTYsys) June 15, 2021
We think that companies seeking to become Pink Current provide great opportunities to investors.
APTY is currently building a financial ecosystem around escrow, payments, and trading services. The platform will be backed with a stablecoin. The ERC-20 token, called Spera, will be pegged to the USD with a 1:1 ratio and will be listed on external exchanges soon. In fact, APTY announced Spera in 2018 and has failed to advance with its development. This is not a good sign, but investors should still monitor APTY, because it might succeed this time. Spera even has a separate website.
Spera will fuel the Verifundr, an escrow and payments platform, enabling participants to transfer dollars, store funds in escrow in order to bind contracts, and later pay others from the credited funds anywhere in the US. Verifundr is designed to act as an ID checker to comply with the KYC and AML rules in the US and 75 other countries.
Spera was meant to be a widely used fiat-to-digital cryptocurrency that is supported and monitored by members of the Verifundr platform to bring trust, safety, and instant payments to parties entering into transactions. According to the initial plan, Verifundr should have been followed by other platform launches as part of a broader ecosystem.
APTY is benefiting from the massive bull run demonstrated by Bitcoin and altcoins in the first quarter of this year. Previously, it was hit by the economic crisis and declining prices of digital currencies, with Bitcoin moving sideways for months. The company had to find excuses and defend its business on social media.
If you can’t say anything nice… https://t.co/Igk4smZw4r
— APT Systems Inc APTY (@APTYsys) September 11, 2020
It remains to be seen what APTY can do these days, but it should be ready for serious competition, as USDC has been the fastest-growing stablecoin and is dominating the DeFi space. Nevertheless, stablecoins are turning into a massive sector, and if APTY can monetize its ecosystem, this will be reflected by the share price.
APTY also owns AUREX Trading and Recovery Inc and plans to launch a cryptocurrency backed by gold and silver.
OTC Stock to Watch #2 DPLS
DarkPulse Inc is another OTC stock on the rise right now. The share price has surged by over 40% on June 16 and has gained over 200% over the last five days.
DPLS is a tech company that manufactures, sells, installs, and monitors laser sensing systems based on its patented BOTDA dark-pulse sensor technology, which provides a data stream of critical metrics for assessing the health and security of infrastructure, including pipelines, oil and gas facilities, as well as mining operations.
Earlier this month, it announced its intention to acquire a controlling stake in Remote Intelligence, LLC and Wildlife Specialists LLC – two companies focused on drone-based, geo-rectified, 3D modeled mapping for industrial applications for the energy sector.
Remote Intelligence offers premier unmanned aerial services as part of its holistic intelligence consultation and solutions. Remote’s focus is aerial drone systems offering rapid comprehensive site mapping and aerial inspection services. They specialize in fully integrated, geo-rectiﬁed, 3D modeled mapping for industrial applications in the energy and environmental industries. Remote also provides video inspection services, aerial, wildlife, and habitat surveys, emergency support services, and comprehensive system design, training, and sales for both the commercial and private sectors.
DarkPulse plans to acquire 60% of Remote Intelligence and 60% of its sister company Wildlife Specialists for the total sum of $1,300,000, with $1 million to be paid in cash and $300,000 to be paid in common shares of DarkPulse, which are scheduled to be paid out equality between the company’s majority shareholder in two tranches, first $300,000 in restricted common shares payable upon closing, with the remaining $1 million cash due within 12 weeks of closing. DPLS will invest additionally in Remote Intelligent’s ongoing operations to expand the business.
The two companies will bring additional revenue to DPLS.
$DPLS Ans to Question: Yes the acquisitions will bring revenues to the company.
— DarkPulse Inc. (@DarkPulseTech) June 15, 2021
DarkPulse COO Kenneth Davidson said that the two acquisitions represented another key piece of the strategy that would enable the company to expand its system capabilities and open new service lines for growth in all three businesses. Speaking about DPLS’s strategy, last month, the company hired Dr. Joseph Catalino Jr. as chief strategy officer. He has worked on major projects within the US Defense Department.
DPLS is really onto something – yesterday, it said it hired a marketing team to work on new branding and logo.
$DPLS We have engaged a large marketing firm to create new marketing materials, videos and custom website including new corporate branding and logo update. We will announce when it’s live. pic.twitter.com/0Z5iciBg4I
— DarkPulse Inc. (@DarkPulseTech) June 15, 2021
DPLS is also one of the most searched stocks right now, and it seems that the momentum will continue.
OTC Stock to Watch #3 ONPH
Oncology Pharma Inc is has been gaining momentum during the last few days, getting closer to its YTD high, which coincides with the highest level since 2016. The $1 billion-dollar company is now trading at $34, up almost 50% during the last 5 days and up 82% during the last month. During the last six months, the OTC stock has surged by an impressive 6,767%, as the company expanded its network of partners.
Our subscribers are familiar with ONPH from our posts that mention Regen BioPharma (OTCMKTS: RGBP), another great OTC stock with long-term potential. RGBP signed two deals with Oncology – one deal focuses on treating pancreatic cancer, and the other one is between Regen’s subsidiary KCL Therapeutics, Inc, and Oncology for the treatment of colon cancer.
The community found out that Oncology updated its website to add Regen under its “Portfolio” page, hinting at a potential buyout. If that’s the case, it’s a win-win situation for both ONPH and RGBP shareholders. However, it’s too early to speculate on that.
Still, ONPH is a good OTC stock on its own. Despite the astronomical increase, there is still room for growth.
ONPH is researching, developing, manufacturing, and commercializing therapeutics for oncology and has a world-class Advisory Board.
OTC Stock to Watch #4 RSHN
RushNet, Inc. is also on the rise. The OTC stock has increased by 216% during the last 5 days.
Investors eye RSHN because it’s been restructuring its business, and that might lead to great opportunities to generate decent returns.
RushNet used to provide beverage products in the US and Canada. However, after a major overhaul, the company turned to biotech solutions as a result of a recent reverse merger.
RushNet was acquired by Chattahoochee Labs through a reverse merger. The latter is rebranding into heliosDX, though it still uses both names as of today. The resulting company holds the RushNet name and the RSHN ticker on the OTC markets. It became Pink current a few days ago.
Chattahoochee Labs/heliosDX provides laboratory testing solutions. It has been operating since 2015 and has experienced profit and rapid growth every year. It is now expecting over $6 million in revenue in 2021.
The company intends to acquire a privately held laboratory with massive revenues to join RSHN. The new laboratory would triple heliosDX’s revenues and quadruple its throughput. It can handle over 5,000 tests each month, with a capacity of 12,000 monthly UDS tests. heliosDX plans to expand its presence on the national stage.
RSHN is turning into something big thanks to the restructuring. We think this is a great stock to hold in your portfolio.
On June 7, RSHN announced that it had officially canceled a proposed reverse split, which added to the bullish sentiment.
THE FINAL NOTE
Insider Financial subscribers got the early jump on APTY and RSHN, which you can join for free here.
Our job is to identify the best OTC stock alerts with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio oriented at penny stocks.
All of the 4 OTC stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever an OTC stock is in the middle of a bull run, we recommend our subscribers to book profits.
There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two OTC stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.